NEW YORK, NY / ACCESSWIRE / April 18, 2016 / Islet Sciences, Inc. (OTC: ISLT) ("Islet Sciences"), a biopharmaceutical company focused on developing new technologies and medicines for the early detection, intervention and pre-treatment to prevent and slow the progression of metabolic disease, today announced that Dr. Gary Blackburn has been appointed to the Board of Directors, effective immediately.
Dr. Blackburn currently serves as CEO of bioMeDx Advisors, a consulting firm he established in 2010. Prior to joining biomeDx, he served as Chief Executive Officer and Director of Claremont BioSolutions from 2010 through 2015, a developer of a proprietary system for very rapid and efficient DNA sample preparation. Dr. Blackburn served as President and CEO of Ohmx Corporation, a protein diagnostics company, from 2005 to 2010. Prior to his tenure at Ohmx Corporation, Dr. Blackburn served as Director of Research at Motorola Life Sciences and VP of Research & Technology at Clinical Micro Sensors (acquired by Motorola for $300 million in 2001) in Pasadena, CA. For two years Dr. Blackburn served on the Motorola team that sold the CodeLink® platform and assets to Amersham Biosciences in 2004 and in 2005 spun-out Clinical Micro Sensors and merged it with another company to create GenMark Molecular Diagnostics. Prior to that, he served as Director of Technology Management at Boehringer Mannheim/Roche Diagnostics where he was responsible for licensing the LightCycler® technology into the company from Idaho Technology, Inc. (now BioFire).
Dr. Blackburn holds a B.S. degree in Chemistry and received his Ph.D. in Biomedical Engineering from the University of Utah in 1983 and completed an NSF Postdoctoral Fellowship at Cornell University in 1985. He has authored numerous publications in the fields of biosensors, immunoassay detection technologies and molecular diagnostics. He is also the inventor or co-inventor of more than 30 U.S. and foreign patents.
"Gary is a prominent industry leader with a distinguished career in Life Science industry," stated, John Steel, Director of Islet Sciences. "We are pleased that he accepted our invitation to join the Islet Sciences Board of Directors. The entire Board looks forward to his insights, input and guidance."
Dr. Blackburn said, "I feel very privileged to have the opportunity to join the Board of Directors of Islet Sciences. The Company has a very promising future and I look forward to working with my fellow directors and the management team to bring the Company to the next level of growth."
About Islet Sciences
Islet Sciences, Inc., a biopharmaceutical company based in New York, NY, is developing new medicines and technologies for the treatment of metabolic disease. For more information, please visit http://www.isletsciences.com.
Certain statements in this press release constitute forward-looking statements. These statements are not historical facts but instead represent only Islet Science's belief regarding future events, many of which, by their nature, are inherently uncertain and outside Islet Science's control. It is possible that actual results will differ, possibly materially, from the anticipated results indicated in these statements. Factors that could affect Islet Science's financial and other results are included in Islet Science's periodic filings with the SEC pursuant to the Securities Exchange Act of 1934.
John Steel, Director
Phone: + 1 858-692-7897
SOURCE: Islet Sciences, Inc.